gnc-039
mAbexperimentalQuad-specific
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 13, 2021 (NCT04794972)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E
- Programmed cell death 1 ligand 1ANTAGONIST
PDL1
- Epidermal growth factor receptor erbB1ANTAGONIST
EGFR antagonist
TNFRSF9 antagonist
Chemistry & pharmacology
- Multi-specific
- Yes (Quad-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04794972 | Phase 1 | Apr 13, 2021 | Baili Pharmaceutical Group, Capital Medical University, SystImmune Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 1 | 1 | 1 | 2021 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| SystImmune Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1